Literature DB >> 10100590

Comparative brain tissue distribution of camptothecin and topotecan in the rat.

S A El-Gizawy1, M A Hedaya.   

Abstract

PURPOSE: The primary objective of this investigation was to compare the extent of brain distribution of the lactone and the carboxylate forms of camptothecin (CPT) and topotecan (TPT) in awake freely moving rats.
METHODS: The plasma concentration-time profiles of the lactone and the carboxylate forms of CPT and TPT were determined simultaneously after a single i.v. administration of the lactone form of each drug. Also, the brain extracellular fluid (ECF) concentration-time profiles were characterized utilizing the microdialysis technique. This technique allowed serial sampling of the brain ECF in awake rats.
RESULTS: CPT-lactone in plasma declined biexponentially with a terminal half-life of 102+/-25.2 min. During the elimination phase, the plasma concentration of CPT-carboxylate was approximately ten times the concentration of CPT-lactone. The brain ECF to plasma distribution ratio measured as the ratio of the AUC in the brain ECF to the AUC in plasma was 0.51+/-0.08 for CPT-lactone, and 0.26+/-0.21 for CPT-carboxylate. The terminal half-life for TPT-lactone was 64.0+/-9.4 min. During the elimination phase, the TPT-carboxylate concentration was higher than that of TPT-lactone but the carboxylate to lactone concentration ratio was much lower than that of CPT. The brain ECF to plasma distribution ratio was 0.38+/-0.12 for TPT-lactone, and 0.21+/-0.06 for TPT-carboxylate.
CONCLUSIONS: CPT and TPT are distributed to the brain ECF most probably by passive diffusion across the blood-brain barrier. Although the brain ECF to plasma distribution ratio for CPT-lactone was higher than that for TPT-lactone, the brain ECF concentrations of TPT-lactone were significantly higher than the CPT-lactone brain ECF concentrations. The relatively high brain ECF to plasma distribution ratio of these two drugs makes them potential candidates for first-line treatment of CNS tumors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10100590     DOI: 10.1007/s002800050908

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

Review 1.  Topotecan: a review of its efficacy in small cell lung cancer.

Authors:  D Ormrod; C M Spencer
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

Review 2.  Pharmacokinetic considerations in the treatment of CNS tumours.

Authors:  Susannah Motl; Yanli Zhuang; Christopher M Waters; Clinton F Stewart
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Hematological response of topotecan in tumor-bearing rats: modeling of the time course of different cellular populations.

Authors:  Cristina Segura; Eva Bandrés; Iñaki F Trocóniz; Jesús García-Foncillas; Onintza Sayar; Carmen Dios-Vieítez; Maria Jesús Renedo; María J Garrido
Journal:  Pharm Res       Date:  2004-04       Impact factor: 4.200

4.  Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive neomorphic mutation?

Authors:  Ryuki Hirano; Heidrun Interthal; Cheng Huang; Tomonori Nakamura; Kimiko Deguchi; Kunho Choi; Meenakshi B Bhattacharjee; Kimiyoshi Arimura; Fujio Umehara; Shuji Izumo; Jennifer L Northrop; Mustafa A M Salih; Ken Inoue; Dawna L Armstrong; James J Champoux; Hiroshi Takashima; Cornelius F Boerkoel
Journal:  EMBO J       Date:  2007-10-18       Impact factor: 11.598

5.  The Influence of Palmatine Isolated from Berberis sibirica Radix on Pentylenetetrazole-Induced Seizures in Zebrafish.

Authors:  Kinga Gawel; Wirginia Kukula-Koch; Dorota Nieoczym; Katarzyna Stepnik; Wietske van der Ent; Nancy Saana Banono; Dominik Tarabasz; Waldemar A Turski; Camila V Esguerra
Journal:  Cells       Date:  2020-05-16       Impact factor: 6.600

6.  Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant Ube3a gene associated with Angelman syndrome.

Authors:  Hyeong-Min Lee; Ellen P Clark; M Bram Kuijer; Mark Cushman; Yves Pommier; Benjamin D Philpot
Journal:  Mol Autism       Date:  2018-08-17       Impact factor: 7.509

7.  Real-Time Positron Emission Tomography Evaluation of Topotecan Brain Kinetics after Ultrasound-Mediated Blood-Brain Barrier Permeability.

Authors:  Andrei Molotkov; Patrick Carberry; Martin A Dolan; Simon Joseph; Sidney Idumonyi; Shunichi Oya; John Castrillon; Elisa E Konofagou; Mikhail Doubrovin; Glenn J Lesser; Francesca Zanderigo; Akiva Mintz
Journal:  Pharmaceutics       Date:  2021-03-18       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.